% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

  • TechInvestor2 TechInvestor2 Feb 27, 2006 9:04 AM Flag

    Bird flu summit has begun

    first talk and speaker:

    "Early warning and surveillance in Europe: are we ready?"

    Koos van der Velden, Chairman
    European Influenza Surveillance Scheme

    See full schedule of talks and speakers at:

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Aethlon CEO to Present at Today's Bird Flu Summit

      SAN DIEGO, Feb 27, 2006 (BUSINESS WIRE) -- Aethlon Medical, Inc. ( AEMD ), a pioneer in developing therapeutic devices for infectious disease, announced that its Chairman and CEO, James A. Joyce, will give a presentation today at Washington DC's first Bird Flu Summit. Mr. Joyce's presentation, The Aethlon Hemopurifier(TM) as a Treatment for Drug Resistant Avian Flu, will begin at 4pm EST. Full details of the conference can be accessed online at

      About Aethlon Medical

      Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at

      Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

      SOURCE: Aethlon Medical, Inc.

      Aethlon Medical, Inc.
      James A. Joyce, 858-459-7800 x301
      Jeff Richardson, 858-459-7800 x302

    • I see that BCRX gets 20 minutes:

      2:40 - 3:00 Antiviral Agents

      C. Shane Arnold, Ph.D. (Confirmed)
      Director, Peramivir Development
      Research Biologist II
      BioCryst Pharmaceuticals, Inc.

3.62+0.16(+4.62%)Jul 29 4:00 PMEDT